ImmunityBio stock has delivered a very strong 321.9% gain over the past three years, yet the current checks on valuation and market pricing point to a company that does not clearly stand out as either a bargain or obviously overpriced.
- The 321.9% return over three years is very large, which makes today’s entry price more important for investors who are considering the next phase of the story.
- Recent approvals and regulatory progress for ANKTIVA can support confidence in ImmunityBio’s revenue potential, while execution risk around commercial uptake and future regulatory decisions may weigh on how much investors are willing to pay for that growth.
- With a value score of 3 out of 6, ImmunityBio presents a mixed picture rather than a clear bargain or a clearly expensive stock.
The issue now is whether ImmunityBio’s current share price already reflects these growth hopes or still leaves room for further upside based on fundamentals.
Does ImmunityBio Look Pricey on Sales?
P/S is a useful lens for ImmunityBio because the company is in a high investment phase where sales traction often matters more than near term profits. ImmunityBio currently trades on a P/S ratio of about 46.8x, compared with a Biotechs industry average of 11.5x and a peer group average of 13.6x. That is a sizeable premium to what investors are paying for many other revenue generating biotech stocks.
The Fair Ratio model, which looks at ImmunityBio’s growth prospects, margins, size and risk profile, suggests a P/S closer to 37.1x would be more in line with those fundamentals. Even with recent ANKTIVA milestones and product revenue headlines, the current multiple still sits well above that level. The stock therefore prices in a lot of optimism around future execution and regulatory outcomes, with limited room for disappointment on this measure.
On the P/S multiple, ImmunityBio stock currently screens as overvalued compared with both its tailored fair ratio and typical biotech peers.
See what the numbers say about this price — find out in our valuation breakdown.
The ImmunityBio Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this ImmunityBio valuation puzzle leaves off and set out clear paths that would make ImmunityBio's current stock price look materially higher or lower based on future growth, margins and earnings. Each narrative links its figures to a specific view on how ImmunityBio's revenue potential, profitability and risk profile could evolve, providing a reference point you can revisit as new information emerges on the Community page.
One of the top community narratives on ImmunityBio: 44% undervalued
"The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, is expected to support a much larger treated patient base over time, which is directly tied to future product revenue growth…"
Read one of the top narratives on ImmunityBio
Do you think there's more to the story for ImmunityBio? Head over to our Community to see what others are saying!
The Bottom Line
On the current market multiples, ImmunityBio screens as overvalued and already prices in a generous set of expectations for ANKTIVA and the wider pipeline. The mixed overall valuation checks suggest investors are not getting an obvious discount for the regulatory and commercial risks that still sit ahead. The crux for both bulls and bears is whether ImmunityBio can translate its recent approvals into durable product revenue and execution that continues to justify such a rich P/S multiple.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com